FDA-Approved Drug Shows Promise Against ALS in Mice
Like 2 Dislike 0 Published on 3 Dec 2019
Ghazaleh Sadri-Vakili, PhD, director of the NeuroEpigenetics Laboratory at the Sean M. Healey & AMG Center for ALS and the MassGeneral Institute for Neurodegenerative Disease, discusses her latest research showing cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of ALS, as recently published in Scientific Reports.